Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes

作者: Joe Anderson , Elshaboury

DOI: 10.2147/PPA.S30949

关键词: Nasal congestionPeripheral edemaProgressive diseaseSinusitisPharmacologyClinical trialSurvival rateEndothelin receptor antagonistAmbrisentanMedicineInternal medicine

摘要: Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that associated with severe functional impairment and poor prognosis. Ambrisentan selective endothelin type A receptor antagonist approved for treatment patients PAH World Health Organization group 1. The efficacy safety ambrisentan has been evaluated in ARIES series (Ambrisentan Treatment Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies), which established its use as both monotherapy or conjunction other therapies. Specifically, effective at increasing exercise tolerance, decreasing risk class deterioration, prolonging time to clinical worsening. Further, favorable effect on mortality, an 88% patient survival rate after two years therapy compared 61% estimated by National Institute Registry. generally well tolerated all groups, main side effects peripheral edema, sinusitis, flushing, nasal congestion considered be mild moderate nature. several qualities potentially make it more acceptable patients, including once-daily administration, limited adverse drug reactions drug-drug interactions, minimal liver enzyme elevation. Because potential teratogenicity ambrisentan, only available through distribution program, ie, LEAP (the Letairis Education Access Program). Ongoing trials will help clarify role PAH.

参考文章(25)
G.F. Alberts, K.A. Peifley, A. Johns, J.F. Kleha, J.A. Winkles, Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop Journal of Biological Chemistry. ,vol. 269, pp. 10112- 10118 ,(1994) , 10.1016/S0021-9258(17)36997-1
Robert A Wise, Cynthia D Brown, Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking Test COPD: Journal of Chronic Obstructive Pulmonary Disease. ,vol. 2, pp. 125- 129 ,(2005) , 10.1081/COPD-200050527
T. Fukuroda, T. Fujikawa, S. Ozaki, K. Ishikawa, M. Yano, M. Nishikibe, Clearance of Circulating Endothelin-1 by ETB Receptors in Rats Biochemical and Biophysical Research Communications. ,vol. 199, pp. 1461- 1465 ,(1994) , 10.1006/BBRC.1994.1395
A. Inoue, M. Yanagisawa, S. Kimura, Y. Kasuya, T. Miyauchi, K. Goto, T. Masaki, The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 86, pp. 2863- 2867 ,(1989) , 10.1073/PNAS.86.8.2863
Gerald Simonneau, Nazzareno Galiè, Lewis J Rubin, David Langleben, Werner Seeger, Guido Domenighetti, Simon Gibbs, Didier Lebrec, Rudolf Speich, Maurice Beghetti, Stuart Rich, Alfred Fishman, Clinical classification of pulmonary hypertension Journal of the American College of Cardiology. ,vol. 43, ,(2004) , 10.1016/J.JACC.2004.02.037
Joe R. Anderson, James J. Nawarskas, Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiology in Review. ,vol. 18, pp. 148- 162 ,(2010) , 10.1097/CRD.0B013E3181D4E921
, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, Corrigendum to: ‘Guidelines for the diagnosis and treatment of pulmonary hypertension’ [European Heart Journal (2009) 30, 2493–2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) European Heart Journal. ,vol. 32, pp. 926- 926 ,(2011) , 10.1093/EURHEARTJ/EHR046
Nazzareno Galiè, Horst Olschewski, Ronald J. Oudiz, Fernando Torres, Adaani Frost, Hossein A. Ghofrani, David B. Badesch, Michael D. McGoon, Vallerie V. McLaughlin, Ellen B. Roecker, Michael J. Gerber, Christopher Dufton, Brian L. Wiens, Lewis J. Rubin, Ambrisentan for the Treatment of Pulmonary Arterial Hypertension Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 Circulation. ,vol. 117, pp. 3010- 3019 ,(2008) , 10.1161/CIRCULATIONAHA.107.742510
Michael McGoon, David Gutterman, Virginia Steen, Robin Barst, Douglas C. McCrory, Terry A. Fortin, James E. Loyd, Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest. ,vol. 126, pp. 14- ,(2004) , 10.1378/CHEST.126.1_SUPPL.14S